Roth Capital Reiterates a Buy Rating on Cytokinetics Inc.

By George MacDonald

In a report released today, Joseph Pantginis from Roth Capital reiterated a Buy rating on Cytokinetics Inc. (NASDAQ: CYTK), with a price target of $18. The company’s shares closed yesterday at $6.90.

Cytokinetics Inc. has an analyst consensus of Strong Buy, with a price target consensus of $13.

Based on Cytokinetics Inc.`s latest earnings report from September 30, the company posted quarterly revenue of $9.42M and quarterly net profit of -$5,971,000. In comparison, last year the company earned revenue of $24.35M and had a net profit of $6.53M.

According to TipRanks, Pantginis is a 1-star analyst with an average return of -1.5% and a 40.5% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, ImmunoCellular Therapeutics, and Cyclacel Pharmaceuticals.

Cytokinetics Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions.